nature medicine

Article

https://doi.org/10.1038/s41591-023-02229-3

Real-world effectiveness of a single dose of mpox vaccine in males

In the format provided by the authors and unedited

STROBE Statement—Checklist of items that should be included in reports of ***cohort studies***

	Item No	Recommendation	Listed in Part/Page
Title and abstract	1	(*a*) Indicate the study's design with a commonly used term in the title or the abstract	Abstract
		(*b*) Provide in the abstract an informative and balanced summary of what was done and what was found	Abstract
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	Intro
Objectives	3	State specific objectives, including any prespecified hypotheses	Intro
Methods			
Study design	4	Present key elements of study design early in the paper	Study Design and timeline section in Methods
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	Detailed in the Methods
Participants	6	(*a*) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	Study participants section in Methods
		(*b*) For matched studies, give matching criteria and number of exposed and unexposed	Study participants section in Methods
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	Defined at the Study design and timeline section in the methods
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	Defined in the data extraction and statistical analysis sections in the methods
Bias	9	Describe any efforts to address potential sources of bias	Described in the limitations section
Study size	10	Explain how the study size was arrived at	Defined at the Study participants section in the methods
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	Described in the statistical analysis section in the methods
Statistical methods	12	(*a*) Describe all statistical methods, including those used to control for confounding	Defined in the statistical analysis section
		(*b*) Describe any methods used to examine subgroups and interactions	There are no subgroup analyses in the study
		(*c*) Explain how missing data were addressed	All data was available for the entire cohort
		(*d*) If applicable, explain how loss to follow-up was addressed	There was no loss for follow-up
		(*e*) Describe any sensitivity analyses	No sensitivity analysis was performed

Results			
Participants	13 *	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	Reported in the Study Participants section
		(b) Give reasons for non-participation at each stage	We include only vaccine- eligible individuals in the study, as reported in the Study Participants section in the results.
		(c) Consider use of a flow diagram	We decided that it is redundant to include a figure
Descriptive data	14 *	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	Detailed in Table 1
		(b) Indicate number of participants with missing data for each variable of interest	There is no missing data in the study
		(c) Summarise follow-up time (eg, average and total amount)	Reported in the Study Participants section
Outcome data	15 *	Report numbers of outcome events or summary measures over time	Reported in the Assessment of vaccine effectiveness section
Main results	16	(*a*) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	Reported in Table 2
		(*b*) Report category boundaries when continuous variables were categorized	Not relevant
		(*c*) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	Not relevant
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	Not applicaple
Discussion			
Key results	18	Summarise key results with reference to study objectives	Reported in the results section
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	Discussed in the limitations
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	Elaborated in the discussion
Generalisability	21	Discuss the generalisability (external validity) of the study results	Elaborated in the discussion
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study	No funding